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Received March 4, 2013; accepted January 3, 2014AbstractBackground: A hospital-based global budget (GB) program was implemented by the Taiwan Bureau of National Health Insurance (TBNHI) to
control the rising costs of medical care. We investigated whether the introduction of the GB program affected prescriptions for second-generation
antipsychotics (SGAs) for schizophrenic outpatients in public and private medical and psychiatric centers.
Methods: The prescription data of schizophrenic outpatients treated between 2001 and 2004 were retrieved from the TBNHI database, which
included outpatients who were diagnosed as having schizophrenia during the period from 1996 to 2001. Because the new health insurance policy
may have had a lag effect on physicians’ decision regarding SGA prescription, we used January 2004 as the timepoint to divide the data, which
was 6 months after GB implementation. Thus, data from the 6-month period immediately after the GB implementation were included in the
pre-GB period. Second-generation antipsychotics included in the study were clozapine, risperidone, olanzapine, quetiapine, ziprasidone, zotepin,
and amisulpride.
Results: After January 2004, the proportion of SGA use in outpatient departments did not show an upward trend, as had been observed in the
pre-GB period, which appeared at a staggering pace lasting for 12 months (p ¼ 0.0004). Compared with medical centers, SGA expenditures in
the psychiatric centers were less affected in the GB period (p < 0.0001). Compared to the private sector, the SGA expenditures in the public
sector were less affected in the GB period (p < 0.019).
Conclusion: We concluded that the GB implementation reduced SGA expenditures significantly. The extent of influence varied among hospitals
(i.e., public versus private, medical versus psychiatric centers), which was most likely caused by financial factors.
Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Keywords: global budgeting; National Health Insurance; schizophreniaConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
* Corresponding author. Dr. Tsuo-Hung Lan, Department of Psychiatry,
Taichung Veterans General Hospital, 200, Section 1, Dongda Road, Taichung
407, Taiwan, ROC.
E-mail address: lonelymanym@yahoo.com.tw (T.-H. Lan).
http://dx.doi.org/10.1016/j.jcma.2014.03.004
1726-4901/Copyright  2014 Elsevier Taiwan LLC and the Chinese Medical Ass1. Introduction
The process of how physicians make decisions with regard
to prescriptions has received greater attention as medical costs
continue to rise, leading to increased expenditures on health
services.1,2 Financial incentives are one factor affectingociation. All rights reserved.
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tures, many cost regulation programs have been implemented
in hospitals by governments and insurance providers. One of
these programs is global budgeting (GB). The implementation
of GB has resulted in a reduction in the number of admissions
and the adoption of an efficient case-mix.4
The GB program was introduced in Taiwan for dental
services in 1998; it was subsequently initiated for Chinese
medicine in 2000, for Western medicine community clinics in
2001, and finally for hospital services (including out- and
inpatient services) in 2002. Among the four GB programs, the
hospital GB program in 2004 accounted for approximately
65% of the total National Health Insurance (NHI) expendi-
ture.5 The current Taiwan GB program is an expenditure-cap
system with a “floating point value” mechanism that is used
to precisely match the predetermined budget using the
formula:
S½ðservice volumeÞðunit pricesÞ ½floating point value ½1
The predetermined budget in a particular year is negotiated
and determined by the previous year’s budget. To meet the
predetermined national expenditure, the total expenditure
claimed is reimbursed based on an adjusted amountdthe
expenditure claimed multiplied by the floating point value.
The floating point value for each hospital is retrospectively
determined every 3 months after the completion of official
review for previous claims. According to the formula, the
floating point value is negatively associated with the nation-
wide service volume, which includes the number of patients
seen and issued medical orders. A higher service volume will
result in a lower floating point value that year for all con-
tracted hospitals. For the purpose of reducing the growing
expenditures on health care, the Bureau of National Health
Insurance (BNHI) in Taiwan introduced “Hospital-based Self-
management” in January 2004, which is a hospital-based GB
program.6 The BNHI encouraged hospitals to participate
voluntarily in the Hospital-based Self-management project.
Many adaptive medical approaches to the implementation of
GB in hospitals have been applied, which include: (1)
persuading and enforcing physicians to prescribe cheaper
drugs; (2) limiting the kinds of drugs drawn into the hospital;
and (3) implementing computerized physician order manage-
ment to reduce drug expenditures.7 Because of the impact of
GB, changes in physicians’ medical behavior such as reduced
prescription of drugs, limited daily service hours in clinics,8
and reduced drug expenditures9 have been noted in studies
conducted in Western countries. The progressive imple-
mentation of GB for different medical services has enabled
researchers to examine the effects of the policy on clear
timelines.
The use of second-generation antipsychotics (SGAs) was
believed to have been reduced by the implementation of GB.
However, in Taiwan and in other nations, there are few data
supporting this postulation. Furthermore, psychiatric services
in Taiwan are provided by four main types of institutions:
medical centers, psychiatric centers, public hospitals, andprivate hospitals. Business operating characteristics such as
finance and management model are assumed to be different
among various types of hospitals.10e12 We postulated that the
incentives for psychiatrists to prescribe SGA vary by hospital
type. To our knowledge, the impact of GB on psychiatrists’
prescriptions of SGA for schizophrenic patients has not been
investigated. Thus, in the present study, we evaluated the ef-
fects of GB on the use of SGA prescriptions by psychiatrists in
various types of hospitals.
This study attempted to answer two questions. First, does
the implementation of hospital-based GB affect psychiatrists’
ongoing prescription of SGA for the treatment of schizo-
phrenia? Second, if this kind of impact does exist, is it
different among various types of hospitals? This study
accordingly examined two hypotheses: (1) after the imple-
mentation of GB, the proportion of SGA use in outpatients
would still show a rising trend, regardless of the effects of GB;
and (2) compared to psychiatrists in the public sector and
psychiatric centers, their counterparts in the private sector and
in medical centers are less likely to decrease their use of SGA
prescriptions.
2. Methods2.1. DatabaseThis study was approved by the Institutional Review Board
of Yuli Hospital, Haulien, Taiwn. Data from between 2001 and
2004 were collected from the NHI database, which included
outpatients who were diagnosed as having schizophrenia
during the period of 1996e2001. The SGAs included in the
study were clozapine, risperidone, olanzapine, quetiapine,
ziprasidone, zotepin, and amisulpride. We set the “dividing
point” as January 2004 for several reasons. First, physicians’
behavior may have been affected by a lag effect after the
implementation of a hospital physician integration strategy.13
Second, during the months of April 2003 through December
2003, an epidemic of severe acute respiratory syndrome may
have prevented patients from going to the hospitals to see their
doctors in person14; they may instead have preferred chronic
disease refill cards to maintain their previous treatments.
Third, after the implementation of GB, the medical charges in
certain areas within hospital departments were still not under
GB control from July 1, 2003 to December 31, 2003.15 The
percentages of SGA expenditures (i.e., the expenditure of
SGA/the expenditure of all antipsychotics) in outpatient de-
partments were calculated for the observation period. We used
descriptive statistics to examine the trends of SGA use.2.2. Data analytic proceduresA general linear regression model (GLM) was applied to
compare trends in the proportion of SGA expenditures before
and after the dividing timepoint. Differences in SGA expen-
diture were examined, based on public sectors versus private
sectors and based on psychiatric centers versus medical cen-
ters. The statistical software of STATA 8.0 (Stata
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NC) were used. Fig. 1 shows the algorithm of data selection,
analysis, and stratification.
The GLM was based on our analysis of the global trends of
SGA use, which were used to set up the regression equation
below:
Proportion¼ interceptþ x1timeþ x2event
þ x3time  event ½2
“Proportion” indicates the proportion of SGA expenditure;
“time” is the number of months between the starting point of
the database and the point under examination. “Event” in-
dicates the implementation of GB; event ¼ 0 is the condition
prior to the implementation of GB and event ¼ 1 is theFig. 1. The algorithm of data selection, analysis, and strcondition after the implementation of GB. To examine
whether the trends in the proportion of SGA expenditure
changed after the dividing timepoint, we determined the sig-
nificance of interactions for “time” and “event”. To investigate
the trends of SGA use between the public sector and private
sector, we set up an equation below:
Proportion ¼ interceptþ x1timeþ x2event
þ x3time  event  type ½3
“Type” indicates the types of sectors; type ¼ 0 indicates the
public sector and type ¼ 1 indicates the private sector. To
examine whether the trends in the proportion of SGA expen-
diture changed after the dividing timepoint between the public
and private sectors, we similarly assessed whether theatification. SGA ¼ second-generation antipsychotic.
Table 1
Multi linear regression model of global budget intervention and time on






A: Time after GBI (mo)* 0.004 0.0003 <0.0001
B: GBI event (reference,
before GBI)*
0.113 0.03 0.0006
Interaction: A  B* 0.004 0.001 0.0004
*Indicates a significance level of p < 0.05.
GBI ¼ global budget intervention; SGA ¼ second-generation antipsychotics.
328 H.-J. Chiu et al. / Journal of the Chinese Medical Association 77 (2014) 325e332interactions between time, event, and type were significant. A
significant interaction term suggested that the usage patterns
of SGAs after the dividing timepoint varied among the
different types of hospitals.
3. Results3.1. Characteristics of the study samplesA total of 43,386 individuals, which included 24,772 males
and 18,614 females, met the criteria for conducting compari-
sons between 137 hospitals in the public sector and 335 hos-
pitals in the private sector, and between 19 medical centers
and 42 psychiatric centers. The following GLM regression
equation was applied (Table 1):
Proportion¼ 0:511þ ð0:004monthÞ þ ð0:113eventÞ
 ð0:004month eventÞ ½4Fig. 2. The trends in the proportion of second-generation antipsychotic expendit
expenditure in July 2002. We believe the implication of global budgeting (GB) in t
expenditure in psychiatry was excluded from the GB system.3.2. Comparison of SGA usage trends prior to and after
the dividing timepointSecond-generation antipsychotic usage continued to rise
after the regulations restricting the use of SGAs were loosened
in September 2000. Prior to the dividing timepoint, the pro-
portion of SGA expenditures continue to rise, whereas there
was no obvious “rising trends” after the dividing timepoint
with the apparent plateau lasting for 12 months. The trends of
SGA expenditures in outpatient departments were significantly
changed after the dividing point (t ¼ 3.9, p ¼ 0.0004;
Fig. 2).3.3. Medical centers versus psychiatric centersThe proportion of SGA expenditures in psychiatric centers
showed a rising trend prior to the implementation of GB (i.e.,
prior to the dividing timepoint); however, the rate of increase
was lower after the dividing timepoint. The proportions in
medical centers showed a rising trend prior to the dividing
timepoint. In the GB period, the proportion appeared initially
to plateau, and thereafter had a slight subsequent decline.
Fig. 3 shows that the trends of SGA use between these two
types of hospitals differed significantly after the dividing
timepoint (t ¼ 5.3, p < 0.0001).3.4. Public sector versus private sectorThe proportion of SGA expenditures in public hospitals
showed a smooth upward trend, whereas the proportion inures. There was an obvious drop in second-generation antipsychotic (SGA)
he psychiatry field at that time may explain the change. Beyond July 2002, the
Fig. 3. The trends in the proportion of second-generation antipsychotic expenditures between medical centers and psychiatric centers in outpatient departments.
GB ¼ global budgeting.
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tion, the trends of SGA use between these two types of hos-
pitals were significantly different after the dividing timepoint
(t ¼ 2.6, p < 0.019; Fig. 4).Fig. 4. The trends in the proportion of second-generation antipsychotic expenditure
departments. GB ¼ global budgeting.4. Discussion
Our findings indicate that the change in the medical pay-
ment system through the implementation of GB did indeeds between private sector institutions and public sector institutions in outpatient
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prescription of SGAs and by the varying prescription pattern
of SGAs based on hospital type. The proportion of SGA ex-
penditures markedly increased after September 2002 when
SGA regulations were loosened. It is reasonable to postulate
that SGA use would continue to rise without the intervention
of regulatory measures. However, this rise in SGA expenditure
was apparently halted after the implementation of GB. Global
budgeting had less impact on the rise in SGA expenditures in
psychiatric centers, compared to medical centers, and GB was
less effective at curbing the increase in SGA expenditures in
the public sector, compared to private hospitals.4.1. Global budgeting and changes in psychiatrists’
medical behavior in TaiwanOur study indicated that the implementation of the GB
program influenced the prescription patterns of psychiatrists.
The financial incentive in GB was a key factor affecting
physicians’ medical behavior. The GB program in Taiwan
adopts the concept of expenditure cap and predetermines the
amount of reimbursement.9 A set of indicators is assessed:
quality indicators, observation indicators, and survey in-
dicators. If the medical cost is above a predetermined upper
limit, the NHI will not cover the amount that exceeds the limit.
If the medical cost is below the upper limit and the standards
of a set of indicators are reached, the hospital can make a
certain amount of profit. As noted in one study,4 hospitals
must reasonably reduce some costs such as pharmaceutical
expenditures to maximize margins. An investigation of a
psychiatric department in a general hospital that had imple-
mented GB revealed the following phenomena: “increased
number of days of prescription for psychiatric outpatient
visits, diminution of the average length of hospitalization, and
a reduction in the kinds of medication typically prescribed
during hospitalization”.134.2. SGA use and types of hospitalsThere are several possible reasons why the prescription
pattern of SGAs could vary by the type of hospital. For the
public sector, there is a weaker motivation to reap profits12 and
to receive the maximum budgetary imbursement from the NHI
program. There is less financial pressure on public hospitals
than on hospitals in the private sector.12 Public hospitals have
consequently shown a slower response to changes in medical
policies.16 In addition, the public sector tends to be held to a
higher standard by the general population to meet their ex-
pectations, and this suggests that physicians in the public
sector are likely to have a stronger concern for the welfare of
the patients.12 Some private hospitals in Taiwan have
conversely adopted a physician fee program to improve phy-
sicians’ performance. Hence, leaders and physicians in public
hospitals are probably less influenced by economic incentives.
Thus, they may tend to prescribe SGAs more in accordance
with their patients’ needs and be less affected by nonclinical
factors.4.3. The significance of SGA usage pattern in public
psychiatric centersIn September 2002, Taiwan’s NHI loosened the regulations
for the use of SGAs, based on their supremacy over first-
generation antipsychotics (FGAs) for patients with schizo-
phrenia. In comparison with the FGA, the SGAs such as ris-
peridone and olanzapine have superior efficacy for negative
symptoms, fewer extrapyramidal side effects, fewer relapses,
and more effective control of psychotic symptoms17 and tar-
dive dyskinesia.18 The SGAs also enhance compliance and life
quality.19 Clozapine, the SGA to be developed, is also regarded
as the most effective medication for treatment-resistant
schizophrenic patients.20 Even though the SGAs are more
expensive than FGAs, the use of SGAs continues to increase
with a corresponding decrease in the use of FGAs in many
countries, which suggests SGAs may be more effective than
FGAs.21e25 In view of the better efficacy for refractory pa-
tients, fewer and less severe neuromuscular side effects, and
improved life quality, SGA use in psychiatric care could
accordingly be an indicator of the quality of treatment in
schizophrenic patients. In our study, the SGA use pattern in
public psychiatric centers appeared least likely to be influenced
by the implementation of GB (i.e., by financial incentives).4.4. Strengths and limitations of the studyOur study is the first investigation to explore the changes in
the psychiatric care-related prescribing patterns of SGAs after
the implementation of GB in Taiwan. Similar studies have
analyzed smaller datasets. However, in the present study a
large sample was obtained from Taiwan’s NHI database,
which is a national database. Furthermore, the database
encompassed various types of hospitals such as psychiatric
centers and medical centers in the public and in the private
sectors, which allowed the authors to determine whether the
type of hospital influenced the impact of GB on SGA use.
Another strength of this study was that an extended dura-
tion of follow-up was used. A 3-year period of observation was
analyzed (1.5 years prior to and 1.5 years after the imple-
mentation of GB). Our study described findings related to the
implementation of a large-scale global budgeting program in
Taiwan, a country with relatively conservative gross domestic
product health costs, and may therefore serve as a useful
example for similar countries looking to develop effective
strategies that can reign in escalating health care costs.
There were nonetheless some limitations in this study.
Because there are strict privacy regulations which limit access
to certain data in the NHI database, it was not possible to
identify which hospitals were taking part in the hospital-based
GB after July 2003. Hence, we used the whole database to
compare the changes of the prescribing pattern after the
implementation of GB in our study. This possibly under-
estimated the extent of decreased use of SGA. However,
global trends of SGA use were obviously changed after the
dividing timepoint. Thus, we are confident that GB did indeed
have an effect on SGA use, even though not all medical or
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period. If drug prices had changed during the observation
period, the analysis of changes in the proportion of drug ex-
penditures could have been confounded. However, there was
no significant change of drug prices during the study period in
our survey.
In addition, education is also a factor that influences phy-
sicians’ medical behavior.3 When the U.S. Food and Drug
Administration (FDA) issued an advisory concerning the
increased risk of suicide attempts among adolescents taking
selective serotonin reuptake inhibitors (SSRIs), the number of
SSRIs prescribed was reduced significantly.26 The effects of
education on physicians’ medical behavior could not be
completely excluded in our study. In recent years, metabolic
syndrome caused by SGAs has become an important
issue.27e29 Many psychiatrists are becoming more cautious
and conservative in prescribing SGAs because of education by
reading current literature, engaging in peer group discussions,
and attending international forums. This effect may be less
pronounced in our study for the following reasons. The impact
of education with regard to complications of SGA was
assumed to be distributed evenly in each type of hospital.
After the implementation of GB, there was no official advisory
in Taiwan on the metabolic side effects of all kinds of SGAs
that was similar to the advisory on SSRIs issued by the FDA in
the United States.
To date, very few studies have examined the effects of
hospital-price regulation on the prescription of psychotropic
agents. More research is needed on this increasingly important
issue because many governments are adopting health policies to
contain expenditure, which could result in reduced quality of
care, especially for those with severe mental illness. We herein
propose several recommendations, based on our findings that
health policymakers may find useful. The government should
identify psychiatric patients with major psychiatric disorders so
that adequate care can be provided, even in the event that the
expenditure cap is exceeded. It is also important to carefully
evaluate the future impact of health policy prior to its imple-
mentation, and subsequently design a more stable strategy to
avoid reducing these patients’ quality of care (e.g., by limiting
the use of SGAs). Furthermore, it is important for the govern-
ment to value the important contribution of public psychiatric
hospitals and tomaximize the financial aid and quality of care in
the public sector. Further suggestions include the following:
after the implementation of GB, outcomes can be compared
regarding medical quality or patients’ quality of life such as
readmission rates, years of hospitalization, suicide rates, and
level of patient satisfaction. In addition, the same model can be
applied to assess the extent of change in the prescription pattern
for other psychotropic medications such as antidepressants,
anxiolytics, and mood stabilizers.
In conclusion, our study has suggested that the imple-
mentation of GB did in fact change physician prescription
behavior. Financial incentives derived from the programs and
compensation schemes have an important role in forming the
adaptive behaviors of hospitals and individual physicians. In
addition, public psychiatric hospitals may offer bettertreatments for patients with chronic schizophrenia who need
long-term institutional care. Our findings demonstrated that
the quality of care in public psychiatric hospitals for chronic
psychotic patients must be enhanced. Health policymakers
must consider the potential negative impact of GB on public
mental health institutions.
The authors hope that the present study will stimulate
further research interest to determine the effects of health
policies on the behavior of psychiatrists and hospitals with a
view of promoting the quality of life and the mental health of
patients in need of psychiatric care.
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